Evaluation of association of HLA and ABCG2 alleles with Severe interstitial lung disease (ILD) and hepatotoxicity in patients receiving abemaciclib

Evaluation of association of HLA and ABCG2 alleles with Severe interstitial lung disease (ILD) and hepatotoxicity in patients receiving abemaciclib - Evaluation of association of HLA and ABCG2 alleles with ILD and hepatotoxicity in patients receiving abemaciclib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046611

Enrollment

236

Registered

2022-01-14

Start date

2022-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients for the secondary research in the nested case control study of abemaciclib-induced interstitial lung disease (NOSIDE).

Exclusion criteria

Exclusion criteria: Not specified

Design outcomes

Primary

Measure	Time frame
To assess the association of HLA and ABCG2 alleles with abemaciclib-induced ILD	—

Secondary

Measure	Time frame
To assess the association of HLA and ABCG2 alleles with abemaciclib-induced hepatotoxicity	—

Countries

Japan

Contacts

Public ContactChiyo IMAMURA

Showa University Advanced Cancer Translational Research Institute

imamurack@med.showa-u.ac.jp03-3784-8145

Outcome results